Report Content
Chapter 1 Methodology & Scope
1.1 Market scope & definitions
1.2 Research design
1.2.1 Research approach
1.2.2 Data collection methods
1.3 Base estimates & calculations
1.3.1 Base year calculation
1.3.2 Key trends for market estimation
1.4 Forecast model
1.5 Primary research and validation
1.5.1 Primary sources
1.5.2 Data mining sources
Chapter 2 Executive Summary
2.1 Industry 3600 synopsis
Chapter 3 Industry Insights
3.1 Industry ecosystem analysis
3.2 Industry impact forces
3.2.1 Growth drivers
3.2.1.1 Growing prevalence of neurological disorders
3.2.1.2 Advancements in drug development
3.2.2 Industry pitfalls & challenges
3.2.2.1 High cost of advanced therapies
3.2.2.2 Side effects and adverse reactions
3.3 Growth potential analysis
3.4 Regulatory landscape
3.5 Future market trends
3.6 Porter's analysis
3.7 PESTEL analysis
Chapter 4 Competitive Landscape, 2023
4.1 Introduction
4.2 Company matrix analysis
4.3 Competitive analysis of major market players
4.4 Competitive positioning matrix
4.5 Strategy dashboard
Chapter 5 Market Estimates and Forecast, By Treatment Type, 2021 – 2032 ($ Mn)
5.1 Key trends
5.2 Medication
5.2.1 Alpha-adrenergic agonists
5.2.2 Antipsychotics
5.2.3 Stimulants
5.2.4 Botulinum toxin injection
5.2.5 Other medication types
5.3 Behavioral therapy
5.3.1 Comprehensive Behavioral Intervention for Tics (CBIT)
5.3.2 Habit reversal training
5.4 Deep brain stimulation (DBS)
5.5 Other treatment types
Chapter 6 Market Estimates and Forecast, By Disease Type, 2021 – 2032 ($ Mn)
6.1 Key trends
6.2 Motor tics
6.3 Vocal tics
Chapter 7 Market Estimates and Forecast, By Age Group, 2021 – 2032 ($ Mn)
7.1 Key trends
7.2 Pediatric
7.3 Adult
Chapter 8 Market Estimates and Forecast, By End-Use, 2021 – 2032 ($ Mn)
8.1 Key trends
8.2 Hospitals
8.3 Specialty clinics
8.4 Homecare settings
8.5 Other end-users
Chapter 9 Market Estimates and Forecast, By Region, 2021 – 2032 ($ Mn)
9.1 Key trends
9.2 North America
9.2.1 U.S.
9.2.2 Canada
9.3 Europe
9.3.1 Germany
9.3.2 UK
9.3.3 France
9.3.4 Spain
9.3.5 Italy
9.3.6 Netherlands
9.3.7 Rest of Europe
9.4 Asia Pacific
9.4.1 China
9.4.2 Japan
9.4.3 India
9.4.4 Australia
9.4.5 South Korea
9.4.6 Rest of Asia Pacific
9.5 Latin America
9.5.1 Brazil
9.5.2 Mexico
9.5.3 Argentina
9.5.4 Rest of Latin America
9.6 Middle East and Africa
9.6.1 South Africa
9.6.2 Saudi Arabia
9.6.3 UAE
9.6.4 Rest of Middle East and Africa
Chapter 10 Company Profiles
10.1 Service Provider
10.1.1 Boston Children's Hospital
10.1.2 Mayo Clinic
10.1.3 Stony Brook Medicine
10.1.4 Massachusetts General Hospital
10.1.5 UPMC Children's Hospital of Pittsburgh
10.2 Medication Manufacturer
10.2.1 AstraZeneca PLC
10.2.2 Bausch Health Companies Inc.
10.2.3 Catalyst Pharmaceuticals, Inc.
10.2.4 Eli Lilly and Company
10.2.5 Emalex Biosciences, Inc.
10.2.6 Novartis AG
10.2.7 Otsuka Pharmaceutical Co., Ltd.
10.2.8 Sun Pharmaceutical Industries Limited
10.2.9 Teva Pharmaceutical Industries Limited
